DOCSLIB.ORG

Solid Tumor – Dr. Gralow TNBC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Solid Tumor – Dr. Gralow TNBC 1 Florida Society of Clinical Oncology New Approved Therapies for Metastatic Triple Negative Breast Cancer Julie Gralow, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology (ASCO) © 2021 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide. TNBC is NOT One Disease! Molecular Subtyping of Triple Negative Breast Cancer (TNBC) Basal-like Immuno-activated • Majority of TNBC • TP53 mutations in >90% • Higher frequency of HRD Basal-like Immuno-suppressed • TP53 mutations in >90% • Lower TILs Mesenchymal • Lower genomic complexity • PIK3CA pathway activation Luminal Androgen Receptor • Lower genomic complexity • PIK3CA, AKT1, NF1, GATA3, CHH1 mutations • Lower ILs Lehmann et al 2011, Burstein et al 2015, Reis-Filho et al 2016, Bareche et al 2018 Drugs for Triple Negative Breast Cancer • Chemotherapy • PARP inhibitors in BRCA1/2+ ▪ Platinum agents more sensitive in ▪ Studies beyond BRCA1/2 TNBC • Androgen Receptor Targeted • Antibody Drug Conjugates Agents ▪ Sacituzumab Govitecan ▪ Bicalutamide, Enzalutamide, • Immune Checkpoint Inhibitors Abiraterone ▪ Atezolizumab ▪ Pembrolizumab Sacituzumab Govitecan Sacituzumab: antibody against Trop-2 (glycoprotein overexpressed on > 90% of TNBC, plus other breast cancer subtypes) Antibody-Drug SN-38: chemotherapy (active metabolite of irinotecan) Conjugates in Triple Negative SN-38 more Humanized Breast Cancer potent than anti-Trop-2 parent antibody compound • FDA accelerated approval metastatic TNBC 5/20 (full approval 4/21) • FDA accelerated approval locally advanced/metastatic urothelial cancer 4/21 ASCENT: Randomized Phase III Trial of Sacituzumab Govitecan vs Treatment of Physician Choice in TNBC Bardia A et al, ESMO 2020 abstract LBA17 • Metastatic triple Sacituzumab govitecan negative breast cancer N= 529 10 mg/kg IV days 1 and 8 every 21 days • > 2 lines chemotherapy in metastatic setting R Treatment of Physician Choice Capecitabine Eribulin Primary endpoint: PFS Vinorelbine Gemcitabine ASCENT: Randomized Phase III Trial of Sacituzumab Govitecan vs Treatment of Physician Choice in Metastatic TNBC Bardia A et al, ESMO 2020 abstract LBA17 R • Main toxicities: neutropenia, anemia, • Median PFS: 5.6 versus 1.7 months, p <0.0001 diarrhea, fatigue • OR: 35% versus 5% • Ongoing studies: Neoadjuvant/adjuvant • Median OS: 12.1 versus 6.7 months, p <0.0001 TNBC, ER+ breast cancer, combinations with other targets, other cancers Anti-PD-1/PD-L1 antibodies approved in TNBC Immune Checkpoint Atezolizumab • Approved in PD-L1+ metastatic TNBC Inhibitors in Triple Negative Pembrolizumab • Approved in PD-L1+ metastatic TNBC Breast Cancer • Also approved in solid tumors with TMB high (≥10 mut/Mb) Immune Checkpoint Inhibitors in TNBC: Atezolizumab • Impassion 130 (Schmid P et al, NEJM 2018) – positive trial ▪ 1st-line metastatic ▪ Nab-paclitaxel +/- atezolizumab ▪ Improved PFS in PD-L1+ (41% of tumors) ▪ Final OS could not be formally tested due to statistical considerations of protocol • Impassion 131 (Miles D et al, ESMO 2020) – negative trial ▪ 1st-line metastatic ▪ Paclitaxel +/- atezolizumab ▪ Did not meet primary endpoint • Impassion 031 (Mittendorf E et al, Lancet 2020) ▪ Neoadjuvant therapy ▪ Nab-paclitaxel followed by AC +/- 1 year atezo ▪ Improved pCR rates with atezo, irrespective of PD-L1 status Immune Checkpoint Inhibitors in TNBC: Pembrolizumab • KEYNOTE 355 Trial (Cortes J et al, Lancet 2020) – positive trial ▪ 1st-line metastatic ▪ Chemo +/- pembrolizumab (nab-paclitaxel, paclitaxel, gemcitabine/carboplatin) ▪ Improved PFS in PD-L1+ ▪ Final OS not yet reported • KEYNOTE 522 Trial (Schmid P et al, NEJM 2020) ▪ Neoadjuvant therapy ▪ Paclitaxel/Carbo followed by AC +/- pembrolizumab x 1 year ▪ Improved pCR rates with pembro, irrespective of PD-L1 status ▪ Reviewed by FDA/ODAC 2/21 - accelerated approval deferred April 27-29, 2021: Oncologic Drugs Advisory Committee (ODAC) Meeting • Updates on 6 accelerated approvals for immune checkpoint inhibitors with confirmatory trials that have not verified clinical benefit • Atezolizumab in combination with nab-paclitaxel for locally advanced/metastatic TNBC expressing PD-L1 • Pembrolizumab for locally advanced/metastatic urothelial carcinoma Atezolizumab for locally advanced/metastatic urothelial carcinoma • Pembrolizumab for locally advanced/metastatic gastric or GE junction adenocarcinoma • Pembrolizumab for hepatocellular carcinoma previously treated with sorafenib • Nivolumab for hepatocellular carcinoma previously treated with sorafenib • Note also: 4 voluntary withdrawals in 2020 in small cell lung cancer and bladder cancer IMpassion130 Phase III Trial: Nab-paclitaxel +/- Atezolizumab in Triple Negative Breast Cancer Schmid P et al, NEJM Oct 2018 N=902 patients Nab-paclitaxel 100 mg/m2 weekly 3 out of 4 weeks + Placebo day 1 • Metastatic breast cancer and 15 • No prior treatment for metastatic disease • ER/PR/HER2 negative Nab-paclitaxel 100 mg/m2 • Stratified by PD-L1 status weekly 3 out of 4 weeks + Atezolizumab 840 mg day 1 and 15 IMpassion130 Phase III Trial: Nab-paclitaxel +/- Atezolizumab in Triple Negative Breast Cancer Schmid P et al, NEJM Oct 2018 1st Interim Analysis: 12.9 months of followup PFS PFS Placebo OS OS Atezo Atezo Placebo ITT 7.2 mo 5.5 mo 21.3 mo 17.6 mo P=0.002 P=0.08 PD-L1 + 7.5 mo 5.0 mo 25 mo 15.5 mo (40.9% of patients) P<0.001 Formal testing not conducted PD-L1 - 5.6 mo 5.6 mo IMpassion130 Phase III Trial: Nab-paclitaxel +/- Atezolizumab in Triple Negative Breast Cancer: Final OS Data Emmens LA et al, ESMO 2020 LBA16 Final OS analysis: 18.8 months follow-up • OS ITT – 21.0 vs 18.7 months • OS PD-L1+ – 25.4 vs 17.9 months, HR 0.67 • OS boundary for statistical significance not crossed in ITT population, which precluded further formal testing in the PD-L1-positive group IMpassion130 Phase III Trial: Nab-paclitaxel +/- Atezolizumab in Triple Negative Breast Cancer Schmid P et al, NEJM Oct 2018 Toxicities Nab-paclitaxel + Nab-paclitaxel + Atezolizumab Placebo Discontinued due to AE 15.9% 8.2% Grade 3, 4 adverse event (most common: 48.7% 42.2% neutropenia, anemia, fatigue, neuropathy) Serious adverse event 22.8% 18.3% Immune-related hypothyroidism 17.3% 4.3% Pneumonitis 3.1% 0.2% Pembrolizumab in Metastatic Breast Cancer with High Tumor Mutational Burden (TMB): Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Alva AS et al, J Clin Oncol 2021 • Eligibility ▪ Metastatic breast cancer ▪ High tumor mutational burden • Treatment: ▪ Pembrolizumab monotherapy: either 2 mg/kg or 200 mg infusions every 3 weeks • Primary end point: disease control (objective response or stable disease > 16 weeks) • Results: ▪ 28 patients enrolled with TMB ranging from 9 to 37 mut/Mb ▪ Disease Control: 37% (95% CI, 21 to 50) ▪ Objective Response: 21% (95% CI, 8 to 41) ▪ Median PFS: 10.6 weeks (95% CI, 7.7 to 21.1) ▪ Median OS: 30.6 weeks (95% CI, 18.3 to 103.3) ▪ No relationship observed between PFS and tumor mutational burden, PD-L1 status not collected Environmental factors (UV, radiation, chemicals)) DNA DAMAGE Normal physiology Cell Death (DNAChemotherapy, replication) Radiotherapy Replication Lesions PARP Inhibitors • Base excision repair Double Strand Breaks PARP1 • Homologous recombination DNA Adducts/Base Damage in Triple Single Strand Breaks BRCA1/BRCA2 • Base excision repair Negative Breast • Base excision repair PARP1 Cancer PARP1 • Combination of BRCA mutation and PARP inhibitor leads to synthetic lethality (cell death) • PARP inhibitors olaparib and talazoparib FDA approved in metastatic breast cancer • “BRCA-like” TNBC with homologous recombination deficiency (HRD) may be vulnerable to PARP inhibition Phase III OlympiAD Trial: Olaparib versus Physician’s Choice Chemotherapy in Metastatic BRCA-mutated Breast Cancer Robson M et al, NEJM 2017 N=302 patients • Metastatic breast Olaparib 300 mg BID Olaparib Chemo cancer • Germline BRCA PFS 7.0 mo 4.2 mo HR 0.58, p < mutation + 2:1 0.001 • HER2 negative Physician’s Choice of Response 60% 29% • Prior treatment with Chemo OS 19.3 mo 19.6 mo anthracycline and (Capecitabine, Vinorelbine, (interim) taxane Eribulin) Phase III EMBRACA Trial: Talazoparib vs Physician’s Choice Chemotherapy in Metastatic BRCA-mutated Breast Cancer Litton J et al, NEJM 2018 N= 431 patients Talazoparib 1 mg po daily Talazoparib Chemo • Metastatic or locally PFS 8.6 mo 5.6 mo HR 0.54, advanced breast p = <0.0001 cancer 2:1 Response 62.6% 27.2% P < 0.001 • Germline BRCA1/2 mutation + Physician’s choice: OS 22.3 mo 19.5 mo P = 0.105 • HER2 negative capecitabine, eribulin, (interim) gemcitabine, vinorelbine PARP Inhibitors in Metastatic Breast Cancer Consider germline genetic testing for metastatic patients: • Patients who meet guidelines for genetic testing based on age and family history • All triple negative • ER+ when thinking of switching to chemo • Additional studies of PARP inhibitors ongoing: • Adjuvant germline BRCA1/2+ breast cancer • OlympiA trial press release 2/21 : “IDMC concluded that trial crossed superiority boundary for iDFS at planned interim analysis” • Patients with germline mutations in other DNA repair genes • Tumors with somatic mutations in BRCA1/2 and other DNA repair genes • TNBC with “BRCAness” features (HRD) PARP Inhibitors Beyond BRCA1/2 TBCRC 048: Phase II Trial of Olaparib in Metastatic Breast Cancer with Germline (other than BRCA1/2) or Somatic Mutations in DNA Repair Genes Tung N et al, J Clin Oncol 2020 Many Additional (but less common) DNA • 54 metastatic breast cancer patents Repair Genes • Germline or somatic
Load more

Recommended publications
  • (Human Papillomavirus 9-Valent Vaccine, Recombinant), for Use In
    tools Approved Drugs FDA has approved a supplemental new drug propelled, joystick-controlled, easy-to-use application (sNDA) for Xtandi® colonoscope system. • The Food and Drug Administration (FDA) (enzalutamide) capsules in advanced has approved a supplemental biologics prostate cancer. • Varian Medical Systems (varian.com) has license application (sBLA) for the use of received 510(k) clearance from the FDA to Arzerra® (ofatumumab) (Genmab A/S, market the Nexus DR, a high resolution genmab.com) in combination with Drugs in the News imaging system for X-ray imaging using a fludarabine and cyclophosphamide for the digital X-ray detector. treatment of patients with relapsed chronic • Genentech (gene.com) has received a lymphocytic leukemia (CLL). second breakthrough therapy designation Approved Genetic Tests & from the FDA for Alecensa® (alectinib) Assays • Amgen (amgen.com) announced that the for the treatment of adult patients with FDA has approved the sBLA for Blincyto® advanced ALK-positive NSCLC who have • AstraZeneca (astrazeneca-us.com) (blinatumomab) to include new data not received prior treatment with an ALK announced that the FDA has approved a supporting the treatment of pediatric patients inhibitor. blood-based companion diagnostic for with Philadelphia chromosome-negative (Ph-) Tagrisso® (osimertinib). relapsed or refractory B-cell precursor acute • AbbVie (abbvie.com) submitted an sNDA lymphoblastic leukemia (ALL). to the FDA for Imbruvica® (ibrutinib) to treat patients with marginal zone lymphoma, • Merck Sharp & Dohme Corp.’s (merck.com) a form of non-Hodgkin’s lymphoma. FDA Approves Two-Dose Keytruda® (pembrolizumab) has received Vaccination Regime FDA approval in first-line non-small cell lung • Fate Therapeutics, Inc.
    [Show full text]
  • Study Protocol
    Official Title: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL CANCER (MODUL) NCT Number: NCT02291289 Document Date: Protocol Version 9: 18-Feb-2020 PROTOCOL TITLE: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL) PROTOCOL NUMBER: MO29112 VERSION NUMBER: 9 EUDRACT NUMBER: 2014-001017-61 IND NUMBER: N/A TEST PRODUCT: Atezolizumab (MPDL3280A, RO5541267) Bevacizumab (RO4876646) Cobimetinib (RO5514041) Pertuzumab (RO4368451) Trastuzumab (RO0452317) Vemurafenib (RO5185426) Cetuximab And combinations thereof MEDICAL MONITOR: Dr. SPONSOR: F. Hoffmann-La Roche Ltd. DATE FINAL: See electronic date stamp below FINAL PROTOCOL APPROVAL Date and Time (UTC) Title Approver's Name 18-Feb-2020 15:44:34 Company Signatory CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. Bevacizumab — F. Hoffmann-La Roche Ltd. Protocol MO29112, Version 9 DATES AMENDED: Version 1: 5 August 2014 Version 2: 29 October 2014 Version 3: 2 February 2015 Version 4: 30 November 2015 Version 5: 11 April 2016 Version 6: 24 November 2016 Version 7: 8 August 2018 Version 8: 19 December 2018 Bevacizumab — F.
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Combinations of Immunotherapy and Radiation Therapy in Head and Neck Squamous Cell Carcinoma: a Narrative Review
    2585 Review Article on Synergy in Action: Novel Approaches to Combining Radiation Therapy and Immunotherapy Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review Thomas J. Hayman1, Aarti K. Bhatia2, Krishan R. Jethwa1, Melissa R. Young1, Henry S. Park1^ 1Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA; 2Section of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT, USA Contributions: (I) Conception and design: TJ Hayman, HS Park; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: TJ Hayman, HS Park; (V) Data analysis and interpretation: TJ Hayman, HS Park; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Henry S. Park, MD, MPH. Assistant Professor of Therapeutic Radiology, Yale School of Medicine, 35 Park Street, Lower Level, New Haven, CT 06520, USA. Email: [email protected]. Abstract: Radiation therapy and systemic therapy are the primary non-surgical treatment modalities for head and neck squamous cell carcinoma (HNSCC). Despite advances in our biologic understanding of this disease and the development of novel therapeutics, treatment resistance remains a significant problem. It has become increasingly evident that the innate and adaptive immune systems play a significant role in the modulation of anti-tumor responses to traditional cancer-directed therapies. By inducing DNA damage and cell death, radiation therapy appears to activate both innate and adaptive immune responses. Immunotherapies targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) also have yielded promising results, particularly in the recurrent/metastatic setting.
    [Show full text]
  • TECENTRIQ® (Atezolizumab) Injection, for Intravenous Use DOSAGE FORMS and STRENGTHS Initial U.S
    of 4-6 cycles. Following completion of chemotherapy, TECENTRIQ 1200 HIGHLIGHTS OF PRESCRIBING INFORMATION mg IV, following by bevacizumab, every 3 weeks. These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for If the first infusion is tolerated, all subsequent infusions may be delivered over TECENTRIQ. 30 minutes. (2.2, 2.3) TECENTRIQ® (atezolizumab) injection, for intravenous use DOSAGE FORMS AND STRENGTHS Initial U.S. Approval: 2016 Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial (3) RECENT MAJOR CHANGES CONTRAINDICATIONS Indications and Usage, Urothelial Carcinoma (1.1) 7/2018 None. (4) Indications and Usage, Non-Small Cell Lung Cancer (1.2) 12/2018 Dosage and Administration (2.3) 7/2018 WARNINGS AND PRECAUTIONS Warnings and Precautions, Pneumonitis (5.1) 12/2018 Immune-Mediated Pneumonitis: Withhold or permanently discontinue Warnings and Precautions, Hepatitis (5.2) 12/2018 based on severity of pneumonitis. (2.4, 5.1) Warnings and Precautions, Colitis (5.3) 12/2018 Immune-Mediated Hepatitis: Monitor for changes in liver function. Warnings and Precautions, Endocrinopathies (5.4) 12/2018 Withhold or permanently discontinue based on severity of transaminase or Warnings and Precautions, Infections (5.6) 12/2018 total bilirubin elevation. (2.4, 5.2) Warnings and Precautions, Infusion-Related Reactions (5.7) 12/2018 Immune-Mediated Colitis: Withhold or permanently discontinue based on severity of colitis. (2.4, 5.3) INDICATIONS AND USAGE Immune-Mediated Endocrinopathies (2.4, 5.4): TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody o Hypophysitis: Withhold based on severity of hypophysitis.
    [Show full text]
  • Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma
    Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma Company Announcement Phase Ib studies of daratumumab in combination with Roche’s immune checkpoint inhibitor atezolizumab in a solid tumor and multiple myeloma to be started Studies conducted under a clinical trial collaboration agreement between Janssen and Roche Copenhagen, Denmark; March 21, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that daratumumab will be investigated in early stage clinical studies in combination with atezolizumab (anti-PD-L1 antibody), in a solid tumor and multiple myeloma. The studies will be conducted under a clinical trial collaboration agreement between Genmab’s licensing partner for daratumumab, Janssen Biotech, Inc., and Genentech, a member of the Roche Group. Atezolizumab is an investigational monoclonal antibody designed to bind to a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells. Janssen will conduct a Phase Ib study of daratumumab in combination with atezolizumab to treat a solid tumor. Genentech will amend an ongoing Phase Ib study to assess atezolizumab in combination with daratumumab, with daratumumab and lenalidomide, and with daratumumab and pomalidomide in relapsed/refractory multiple myeloma (NCT02431208). The studies are expected to start enrolling patients later this year and information about the studies will be posted on www.clinicaltrials.gov. “We are very excited about the start of the first study to investigate daratumumab in a solid tumor, potentially expanding its clinical utility beyond hematological cancers. We are equally excited about testing daratumumab in combination with an immune checkpoint inhibitor, such as Roche’s anti-PDL1, atezolizumab, in multiple myeloma.
    [Show full text]
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • A Phase Ib/II Study Evaluating the Safety and Efficacy Of
    Official Title: A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT Number: NCT02729896 Document Date: Protocol Version 8: 07-November-2018 PROTOCOL TITLE: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PROTOCOL NUMBER: BO29561 VERSION NUMBER: 8 EUDRACT NUMBER: 2015-004845-25 IND NUMBER: 128036 TEST PRODUCT: Obinutuzumab (RO5072759) Rituximab (RO0452294) Atezolizumab (RO5541267) Polatuzumab vedotin (RO5541077) MEDICAL MONITOR: , Ph.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 12 November 2015 DATES AMENDED: Version 2: 14 January 2016 Version 3: 28 June 2016 Version 4: 17 November 2016 Version 5: 4 May 2017 Version 6: 21 December 2017 Version 7: 1 May 2018 Version 8: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 07-Nov-2018 02:00:10 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F.
    [Show full text]
  • Study Protocol
    Official Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study Of The Efficacy And Safety Of Trastuzumab Emtansine In Combination With Atezolizumab Or Atezolizumab- Placebo In Patients With HER2-Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab And Taxane Based Therapy NCT Number: NCT02924883 Document Date: Protocol Version 3: 09 Aug 2017 PROTOCOL TITLE: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY PROTOCOL NUMBER: WO30085 VERSION NUMBER: 3 EUDRACT NUMBER: 2015-004189-27 IND NUMBER: 71,072 TEST PRODUCT: Trastuzumab Emtansine (RO5304020) Atezolizumab (RO5541267) MEDICAL MONITOR: , M.D. , Ph.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 14 April 2016 DATE AMENDED: Version 2: 21 December 2016 Version 3: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 09-Aug-2017 16:54:13 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board.
    [Show full text]
  • Cyramza® (Ramucirumab)
    Cyramza® (ramucirumab) (Intravenous) -E- Document Number: MODA-0405 Last Review Date: 07/01/2021 Date of Origin: 09/03/2019 Dates Reviewed: 09/2019, 10/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 07/2021 I. Length of Authorization Coverage will be provided for 6 months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Cyramza 100 mg/10 mL: 4 vials per 14 days • Cyramza 500 mg/50 mL: 2 vials per 14 days B. Max Units (per dose and over time) [HCPCS Unit]: Gastric, Gastroesophageal, HCC, and Colorectal Cancer: • 180 billable units every 14 days NSCLC: • 240 billable units every 14 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND Universal Criteria 1 • Patient does not have uncontrolled severe hypertension; AND • Patient must not have had a surgical procedure within the preceding 28 days or have a surgical wound that has not fully healed; AND Gastric, Esophageal, and Gastro-esophageal Junction Adenocarcinoma † Ф 1-3,5-7,14,17,2e,5e • Used as subsequent therapy after fluoropyrimidine- or platinum-containing chemotherapy; AND • Used as a single agent OR in combination with paclitaxel; AND o Used for one of the following: Moda Health Plan, Inc. Medical Necessity Criteria Page 1/27 Proprietary & Confidential © 2021 Magellan Health, Inc. – Patient has unresectable locally advanced, recurrent, or metastatic disease; OR – Used as palliative therapy for locoregional disease in patients who are not surgical candidates
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • 1 Oncologic Drugs Advisory Committee (ODAC)
    Oncologic Drugs Advisory Committee (ODAC) Meeting April, 27, 2021 BLA# 761034/Supplement 18 Drug name: TECENTRIQ® (atezolizumab) Applicant: Genentech, Inc. Combined FDA and Applicant ODAC Briefing Document Advisory Committee Briefing Materials: Available For Public Release 1 DISCLAIMER STATEMENT The attached package contains background information prepared by the Applicant and the Food and Drug Administration (FDA) for the panel members of the advisory committee. The package contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the drug TECENTRIQ® (also known as atezolizumab) to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting. 2 Table of Contents Table of Tables .........................................................................................................................
    [Show full text]